A leading Stanford researcher has thrown cold water on the race to bring gene-editing therapies into human trials, saying the technology is not yet ready. The expert, speaking at a recent conference, stressed that the science still has too many unknowns to safely test on people.
The gap between promise and proof
Gene editing has long been hailed as a potential cure for genetic diseases, but the Stanford expert argues that the gap between laboratory success and clinical safety remains wide. The researcher pointed to off-target effects, where the editing tool may alter unintended parts of the genome, as a major unresolved risk. Even with advances in precision, the expert said, the current tools are not precise enough to guarantee patient safety.
Why the caution matters now
In the United States, where biotech companies are pushing to move gene-editing treatments from the lab to the clinic, this warning comes at a critical time. The expert noted that while animal studies have shown promise, they do not fully predict human responses. Local researchers and regulators are paying close attention, as the pressure to fast-track therapies grows. The Stanford expert urged the scientific community to slow down and invest more in basic research before any human trials begin.
A call for patience in a fast-moving field
The expert's message is not a rejection of gene editing, but a call for patience. The technology could eventually transform medicine, but only if it is developed responsibly. For now, the priority should be understanding the risks and refining the tools. The scientific community, especially in the US, is listening, even as commercial interests push for speed. The future of gene editing depends on getting it right, not just getting it first.
